01:02 PM EST, 12/03/2024 (MT Newswires) -- Shares of Janux Therapeutics ( JANX ) were rallying Tuesday after the biopharmaceutical company reported late Monday positive interim clinical data for its JANX007 clinical program in prostate cancer patients.

The company said high prostate-specific antigen response rates and deep PSA declines were observed in all doses in the phase 1a clinical trial, which also showed that JANX007 has a well-tolerated safety profile.

Janux said that based on these results, two once-weekly step dose regimens have been identified for phase 1b expansion trials.

Price: 61.56, Change: +21.38, Percent Change: +53.21